(Q44442589)

English

Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors

scientific article published in February 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 December 2017

Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors (English)

1 reference

Europe PubMed Central

3 December 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

circulatory system

1 reference

based on heuristic

inferred from title

Giuseppe Derosa

1

1 reference

Europe PubMed Central

3 December 2017

author name string

Amedeo Mugellini

2

1 reference

Europe PubMed Central

3 December 2017

Leonardina Ciccarelli

3

1 reference

Europe PubMed Central

3 December 2017

Giuseppe Crescenzi

4

1 reference

Europe PubMed Central

3 December 2017

Roberto Fogari

5

1 reference

Europe PubMed Central

3 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 February 2003

1 reference

Europe PubMed Central

3 December 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

3 December 2017

25

1 reference

Europe PubMed Central

3 December 2017

2

1 reference

Europe PubMed Central

3 December 2017

472-484

1 reference

Europe PubMed Central

3 December 2017

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The association of glycemia and cause-specific mortality in a diabetic population

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

NIDDM and its metabolic control predict coronary heart disease in elderly subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipoprotein(a). A genetic risk factor for premature coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Glimepiride. A review of its use in the management of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of total serum insulin (IRI) in insulin-treated diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The Glycosylation of Hemoglobin: Relevance to Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

[Rapid physiological coagulation method in determination of fibrinogen]

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical pharmacokinetics and pharmacodynamics of repaglinide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical profile of glimepiride

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipoprotein(a) and diabetes. An update

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Metformin and lipoprotein(a) levels

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Increase of lipoprotein (a) with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Troglitazone's effect on lipoprotein(a) levels

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential response of plasma lipoprotein(a) and apolipoprotein B in NIDDM subjects treated with acarbose

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(03)80090-5

1 reference

Europe PubMed Central

3 December 2017

1 reference

Europe PubMed Central

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44442589&oldid=2023670929"